Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6

November 4, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Nov. 4, 2020-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra’s novel therapeutic approaches to treating anterior and posterior segment ocular disease at the Eyecelerator 2020 Virtual Conference on Friday, November 6, 2020. Dr. Brady’s presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as part of Company Showcase III, “Advancing Trials in the Public Eye.”

The presentation will highlight data from clinical trials of Aldeyra’s lead drug candidates, 0.25% reproxalap ophthalmic solution and ADX-2191 (0.8% methotrexate intravitreal injection). Reproxalap is in Phase 3 clinical trials for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. ADX-2191 is in Phase 3 testing for the prevention of proliferative vitreoretinopathy (PVR), a rare but serious sight-threatening retinal disease with no approved treatment.

Eyecelerator, a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS), is designed to connect entrepreneurs, investors, businesses and ophthalmologists to advance ophthalmic innovation. To register for the Eyecelerator 2020 Virtual Conference, visit

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit and follow us on LinkedIn, Facebook, and Twitter.

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300

Source: Aldeyra Therapeutics, Inc.

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video